Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03754140




Registration number
NCT03754140
Ethics application status
Date submitted
31/10/2018
Date registered
27/11/2018

Titles & IDs
Public title
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Scientific title
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Secondary ID [1] 0 0
HREC/18/RPAH 621
Universal Trial Number (UTN)
Trial acronym
INTRANS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
In-Transit Metastasis of Cutaneous Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma
Cancer 0 0 0 0
Non melanoma skin cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Polidocanol Injection

Experimental: Polidocanol Injection - Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion


Treatment: Drugs: Polidocanol Injection
Sclerotic agent
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Clinical efficacy of interlesional polidocanol injection assessed by the size of in transit melanoma metastases after treatment
Timepoint [1] 0 0
8 weeks
Secondary outcome [1] 0 0
Incidence of treatment related adverse events
Timepoint [1] 0 0
8 weeks
Secondary outcome [2] 0 0
Bystander treatment effect on untreated intransit melanoma metastases
Timepoint [2] 0 0
8 weeks
Secondary outcome [3] 0 0
Bystander treatment effect on the proportion of tumour infiltrating immune markers in treated and untreated melanoma lesions
Timepoint [3] 0 0
8 weeks
Secondary outcome [4] 0 0
Bystander treatment effect on tumour viabilty in treated and untreated melanoma lesions
Timepoint [4] 0 0
8 weeks

Eligibility
Key inclusion criteria
* Histologically confirmed in transit and/or cutaneous melanoma metastases unsuitable for, or with progressive disease despite systemic, surgical, intra-arterial, topical or radiation therapies
* A minimum of 2 accessible lesions
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Periocular lesions
* Severe renal impairment defined as an estimated glomerular filtration rate <20ml/min/1.73sqm
* Sever liver function abnormality defined as aspartate aminotransferase and / or alanine aminotransferase > 3 x upper limit of normal and / or bilirubin > 1.5 x upper limit of normal
* known hypersensitivity to polidocanol or its exipients
* Patients unavailble for the full study duration (of a 4 week screening period and 8 week treatment period) because of general frailty, geographical or social reasons
* Pregnant or breast feeding female patients
* Patients receiving topical or radiation therapy to the in transit and / or cutaneous lesions within 4 weeks of planned start of study treatment (patients receiving current systemic immunotherapy which is deemed appropriate to continue, despite progression of disease in the skin, in order to reduce the likelihood of visceral metastases are eligible)
* Patients receiving sclerosants for other indications within 4 weeks of planned start of study treatment or during study treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Withdrawn
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/05/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2022
Actual
Sample size
Target
Accrual to date
Final
0
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown

Funding & Sponsors
Primary sponsor type
Other
Name
Melanoma Institute Australia
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Diona Damian
Address 0 0
Royal Prince Alfred Hospital, Sydney, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03754140